Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2415
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept ; volume:18 ; number:1 ; day:22 ; month:6 ; year:2018 ; pages:1-8 ; date:12.2018
BMC ophthalmology ; 18, Heft 1 (22.6.2018), 1-8, 12.2018
- Creator
-
Tyagi, Pallavi
- Contributor
-
Juma, Zain
Hor, Yong Keen
Scott, Neil W.
Ionean, Andreea
Santiago, Cynthia
SpringerLink (Online service)
- DOI
-
10.1186/s12886-018-0824-0
- URN
-
urn:nbn:de:101:1-2018090119423763665348
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tyagi, Pallavi
- Juma, Zain
- Hor, Yong Keen
- Scott, Neil W.
- Ionean, Andreea
- Santiago, Cynthia
- SpringerLink (Online service)
Other Objects (12)
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia